Genomics In Cancer Care Market Size, Share and Growth Outlook, 2026

Genomics In Cancer Care Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Genomics In Cancer Care Market size is forecast to increase from $27.71 Billion in 2026 to $85.95 Billion in 2034 at a CAGR of 15.2% between 2026 and 2034.

The Genomics In Cancer Care market report provides detailed analysis and outlook of Genomics In Cancer Care segments including By Product & Service (Consumables & Reagents, Instruments & Systems, Analytical Software & Services), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence In Situ Hybridization, Comparative Genomic Hybridization, Microarrays ), By Application (Cancer Diagnosis & Early Detection, Prognosis & Risk Assessment, Companion Diagnostics & Treatment Selection, Therapy Monitoring & Minimal Residual Disease ), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Hematologic, Melanoma), By Sample Type (Tissue Biopsy, Liquid Biopsy ), By End-User (Hospitals & Cancer Centers, Diagnostic & Reference Laboratories, Pharmaceutical & Biotechnology Firms, Academic & Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Genomics in Cancer Care Industry Overview

Comprehensive Genomic Profiling Transforms Cancer Management

The genomics in cancer care industry continues to expand as healthcare providers increasingly utilize genomic testing to guide diagnosis, treatment selection, disease monitoring, and clinical trial enrollment. Advances in precision oncology are enabling clinicians to identify actionable mutations, match patients with targeted therapies, and improve clinical outcomes through personalized treatment strategies. The integration of genomic technologies into routine oncology practice is strengthening the role of molecular medicine across multiple cancer types.

Precision Oncology Evidence Reinforces Genomic Testing Adoption

Recent clinical findings continue to demonstrate the value of comprehensive genomic profiling in cancer care. Following the 2026 ASCO Annual Meeting, Eli Lilly reported positive Phase 3 results from the LIBRETTO-432 trial evaluating Retevmo (selpercatinib) in patients with early-stage RET fusion-positive non-small cell lung cancer. The study demonstrated an 83% reduction in the risk of disease recurrence or death, reinforcing the importance of identifying RET gene fusions through genomic testing. These results underscore the growing necessity of molecular diagnostics across all stages of lung cancer management and support broader adoption of genomic screening within oncology care pathways.

AI-Driven Clinical Trial Optimization Improves Patient Access

Artificial intelligence is playing an increasingly important role in connecting patients with precision oncology treatment opportunities. GenomOncology has expanded its clinical trial optimization services through strategic collaborations designed to improve enrollment efficiency and trial accessibility. Partnerships with WeTrials and the Oregon Health & Science University Knight Diagnostics Lab leverage AI-powered technologies to identify eligible patients and streamline access to precision medicine studies. These initiatives help address challenges in clinical trial recruitment while supporting the development of targeted cancer therapies.

Data-Driven Oncology Ecosystems Support Personalized Treatment

The genomics in cancer care market is increasingly characterized by integrated data-driven platforms that combine genomic testing, clinical decision support, and trial-matching capabilities. Healthcare organizations, diagnostic laboratories, and technology providers are working together to build precision oncology ecosystems that enable more effective treatment planning and patient management. As genomic information becomes more deeply embedded within cancer care workflows, the industry continues to advance toward highly personalized treatment models that improve outcomes and expand access to innovative therapies.

Genomics In Cancer Care Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Genomics In Cancer Care market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Illumina, Inc., F. Hoffmann-La Roche Ltd (Foundation Medicine), Thermo Fisher Scientific Inc., Agilent Technologies, Inc., QIAGEN N.V., Myriad Genetics, Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Quest Diagnostics Incorporated, Pacific Biosciences of California, Inc. (PacBio). The Genomics In Cancer Care market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Genomics In Cancer Care industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Genomics In Cancer Care Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Genomics In Cancer Care companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Genomics In Cancer Care markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Genomics In Cancer Care Market Competitive Benchmarking and Company Analysis

Leading companies in Genomics In Cancer Care industry include- Illumina, Inc., F. Hoffmann-La Roche Ltd (Foundation Medicine), Thermo Fisher Scientific Inc., Agilent Technologies, Inc., QIAGEN N.V., Myriad Genetics, Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Quest Diagnostics Incorporated, Pacific Biosciences of California, Inc. (PacBio). The Genomics In Cancer Care market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Genomics In Cancer Care Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Genomics In Cancer Care market remains one of the strongest-performing segments in the country.
The US Genomics In Cancer Care Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Genomics In Cancer Care market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Genomics In Cancer Care industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Genomics In Cancer Care markets

Canada's strong Genomics In Cancer Care sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Genomics In Cancer Care market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Genomics In Cancer Care Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Genomics In Cancer Care market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Genomics In Cancer Care population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Genomics In Cancer Care industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Genomics In Cancer Care market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Genomics In Cancer Care sales through 2034

France Genomics In Cancer Care companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Genomics In Cancer Care Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Genomics In Cancer Care distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Genomics In Cancer Care Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Genomics In Cancer Care market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Genomics In Cancer Care industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Genomics In Cancer Care industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Genomics In Cancer Care Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Genomics In Cancer Care market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Genomics In Cancer Care market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Genomics In Cancer Care Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Genomics In Cancer Care Market Segmentation

By Product & Service
Consumables & Reagents
Instruments & Systems
Analytical Software & Services
By Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Fluorescence In Situ Hybridization
Comparative Genomic Hybridization
Microarrays
By Application
Cancer Diagnosis & Early Detection
Prognosis & Risk Assessment
Companion Diagnostics & Treatment Selection
Therapy Monitoring & Minimal Residual Disease
By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Hematologic
Melanoma
By Sample Type
Tissue Biopsy
Liquid Biopsy
By End-User
Hospitals & Cancer Centers
Diagnostic & Reference Laboratories
Pharmaceutical & Biotechnology Firms
Academic & Research Institutes

Top Companies in Genomics In Cancer Care Industry

Illumina, Inc.
F. Hoffmann-La Roche Ltd (Foundation Medicine)
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
QIAGEN N.V.
Myriad Genetics, Inc.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Quest Diagnostics Incorporated
Pacific Biosciences of California, Inc. (PacBio)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025